Now Approved in Moderate-to-Severe Asthma

DUPIXENT is indicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma.

Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

ACQ-5, Asthma Control Questionnaire, 5-item version; AQLQ(S), Asthma Quality of Life Questionnaire, Standardized Version; FEV1, forced expiratory volume in 1 second; MOA, mechanism of action; OCS, oral corticosteroid.

Reference: DUPIXENT Prescribing Information. October 2018.